QTTB

Q32 Bio Inc. develops targeted immune therapeutics for autoimmune and inflammatory diseases, focusing on conditions such as alopecia areata. The company is advancing a Phase 2 program for its lead product candidate, Bempikibart (ADX-914), which is a fully human anti–interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody designed to modulate immune function by blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling.